“Study DetailsThe study involved 269,725 male participants with an average age of 59 who were freshly detected with erectile dysfunction. The study compared the 55% of the individuals who had prescriptions for erectile dysfunction drugs to the 45% who did not have prescriptions.During the research study, 1,119 people developed Alzheimers disease.Among the participants taking erectile dysfunction drugs, 749 established Alzheimers illness, which corresponds to a rate of 8.1 cases per 10,000 person-years.”Reference: “Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer DiseaseA Cohort Study” by Matthew Adesuyan, Yogini H. Jani, Dana Alsugeir, Robert Howard, Chengsheng Ju, Li Wei and Ruth Brauer, 7 February 2024, Neurology.DOI: 10.1212/ WNL.0000000000209131 The research study was based on prescription records.
A recent study shows a potential link in between erectile dysfunction drugs and a lower risk of establishing Alzheimers illness, revealing an 18% minimized risk amongst users after adjusting for numerous elements. While promising, the findings underscore the need for further research to explore the underlying mechanisms and benefits, and whether these outcomes use to women.According to brand-new research study released in Neurology, the medical journal of the American Academy of Neurology, drugs for dealing with impotence might likewise be linked to a lower danger of Alzheimers disease. Nevertheless, the study suggests a connection rather than showing that erectile dysfunction medications straight decrease the risk of Alzheimers disease.Erectile dysfunction drugs, which work by dilating capillary to allow more blood to flow through, were very first developed to deal with hypertension. A new research study recommends that the drugs may be connected to a minimized threat of Alzheimers disease.”Although were making development with the new treatments for Alzheimers illness that work to clear amyloid plaques in the brain for people with early phases of the disease, we frantically need treatments that can prevent or postpone the advancement of Alzheimers illness,” stated study author Ruth Brauer, Ph.D., of the University College London in the United Kingdom. “These outcomes are encouraging and warrant additional research study.”Study DetailsThe research study included 269,725 male participants with an average age of 59 who were recently diagnosed with impotence. Participants did not have any memory or thinking problems at the start of the study. They were then followed for approximately five years. The research study compared the 55% of the participants who had prescriptions for erectile dysfunction drugs to the 45% who did not have prescriptions.During the study, 1,119 individuals established Alzheimers disease.Among the individuals taking erectile dysfunction drugs, 749 developed Alzheimers disease, which corresponds to a rate of 8.1 cases per 10,000 person-years. Person-years represent both the number of people in the research study and the quantity of time everyone spends in the study. Amongst those who did not take the drugs, 370 established Alzheimers disease, which corresponds to a rate of 9.7 cases per 10,000 person-years. When researchers adjusted for other elements that could affect the rate of Alzheimers disease, such as age, cigarette smoking status, and alcohol consumption, they discovered that people who took erectile dysfunction drugs were 18% less most likely to develop Alzheimers than individuals who did not take the drugs.The association was greatest in those who were provided the most prescriptions over the study period.Future Research Directions”More research study is needed to validate these findings, find out more about the possible benefits and systems of these drugs, and look into the optimal dose,” Brauer said. “A randomized, controlled trial with both female and male individuals is necessitated to figure out whether these findings would apply to females also.”Reference: “Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer DiseaseA Cohort Study” by Matthew Adesuyan, Yogini H. Jani, Dana Alsugeir, Robert Howard, Chengsheng Ju, Li Wei and Ruth Brauer, 7 February 2024, Neurology.DOI: 10.1212/ WNL.0000000000209131 The research study was based on prescription records. A restriction of the study is that researchers did not have info on whether participants really filled the prescriptions and used the drugs.
